RAPP · CIK 0002012593
Rapport Therapeutics, Inc.
What Rapport Therapeutics, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Rapport Therapeutics, Inc. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 84stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Rapport Therapeutics, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Rapport Therapeutics, Inc. Form 10-K for fiscal year 2025 and Rapport Therapeutics, Inc. Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
RAPP
Description
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company in Boston, Massachusetts that develops small molecule precision medicines for neurological and psychiatric disorders using a receptor associated protein (RAP) technology platform. Its lead candidate RAP-219 is an AMPA receptor negative allosteric modulator targeting TARP gamma-8. A Phase 2a trial in drug-resistant focal onset seizures met its primary and secondary endpoints in September 2025, and the Phase 3 program began in the second quarter of 2026. A Phase 2 trial in bipolar mania is enrolling, with topline results expected in October 2026, and a Phase 3 trial in primary generalized tonic-clonic seizures is planned for the first half of 2027. RAP-641, an alpha-6 beta-4 nicotinic acetylcholine receptor agonist, is in IND-enabling work for chronic pain and migraine. Rapport licensed its TARP gamma-8 and nAChR assets from Janssen in August 2022. In March 2026 it licensed Greater China rights to RAP-219 to Tenacia Biotechnology for $20.0 million upfront plus up to $308.0 million in sales-based milestones and tiered royalties. It reported no revenue and a $111.5 million net loss in 2025, then $20.0 million of collaboration revenue and a $76.5 million net loss in the first half of 2026. Cash and short-term investments were $436.1 million at 30 June 2026. Rapport had 84 full-time employees at 31 December 2025.
Who owns Rapport Therapeutics, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 141 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
141 managers reported a position, together holding 52.5m shares, or 109.7% of the company. The 40 largest are listed. Percentages are of the 47.8m shares outstanding at 4 May 2026, the count in force when this quarter was measured rather than the count today.
This adds up to more than the whole company, and that is what the filings say. A 13F total can exceed 100% because the same share can be reported twice: when a holder lends stock, the borrower sells it to someone else, and both the lender's manager and the new buyer's manager report it. The gap tracks how heavily a stock is shorted. It is a property of 13F rather than a fault in this data, so it is shown as filed, and it cannot be used as evidence that a particular holder's stake is large.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 75383L102, held by ameriprise, bank-of-america, blackrock, bny-mellon, capital-group, citigroup, fidelity-fmr, geode, goldman-sachs, invesco, johnson-johnson, jpmorgan, metlife, morgan-stanley, northern-trust, pnc, prudential-financial, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.